Study of Immune Cells in Breast Tumors
Author Information
Author(s): H.L. Whitwell, H.P.A. Hughes, M. Moore, A. Ahmed
Primary Institution: Department of Immunology, Paterson Laboratories, Christie Hospital and Holt Radium Institute, Manchester
Hypothesis
How do major histocompatibility antigens and leucocyte infiltration differ between benign and malignant breast tumors?
Conclusion
Malignant breast tumors have a greater number of T lymphocyte infiltrates compared to benign tumors, but there is no simple correlation with the expression of MHC Class I or Class II antigens on the tumor cells.
Supporting Evidence
- T lymphocyte infiltrates were more numerous in malignant tumors compared to benign ones.
- Leucocytes were primarily confined to the stroma in malignant tumors.
- Approximately 75% of the leucocytes were T lymphocytes in malignant tumors.
- There was no correlation between T cell infiltration and the HLA status of epithelial cells.
Takeaway
This study looked at how immune cells behave in breast tumors. It found that cancerous tumors have more immune cells, but these cells don't always react the same way as in non-cancerous tumors.
Methodology
The study used indirect immunoperoxidase technique on tissue sections from 16 benign and 17 malignant breast tumors to analyze the expression of MHC antigens and leucocyte infiltration.
Potential Biases
Potential bias due to the variability in antigen expression and the difficulty in identifying specific cell types.
Limitations
The study was limited to a single time point in the disease's natural history and may have introduced sampling errors.
Participant Demographics
Patients with benign lesions were aged 22-65 years, while those with malignant tumors were aged 50-78 years.
Want to read the original?
Access the complete publication on the publisher's website